Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock

Trevi Therapeutics (TRVI) has priced an underwritten public offering of 17.4 million common shares at $5.75 per share, expected to generate gross proceeds of approximately $100 million to fund clinical development of Haduvio. Underwriters, including Morgan Stanley and Leerink Partners, have a 30-day option to purchase up to 2.61 million additional shares. The offering is expected to close around June 5, 2025, with final terms to be disclosed in a final prospectus supplement.

Analysis

Trevi Therapeutics, Inc. (TRVI) has priced an underwritten public offering of 17.4 million common shares at $5.75 per share, aiming to generate gross proceeds of approximately $100 million, before expenses. This offering price represents a notable discount to TRVI's previous closing price of $6.58 on Wednesday (which itself was an increase of 10.59% on the day) and its subsequent after-hours trading price of $6.51. The proceeds are earmarked for the clinical development of Haduvio, Trevi's lead candidate for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough. The offering, managed by joint book-runners including Morgan Stanley and Leerink Partners, includes a 30-day option for underwriters to purchase up to an additional 2.61 million shares, potentially increasing the total capital raised. Expected to close around June 5, 2025, this capital infusion is critical for the clinical-stage biopharmaceutical company to advance its primary asset, Haduvio, through further development stages. However, the issuance of new shares will result in dilution for existing shareholders. The overall market sentiment towards this news is mixed (sentiment score 0.0), with TRVI's specific sentiment being only slightly positive (0.3), reflecting the balance between the necessity of funding for a development-stage biotech and the immediate dilutive impact of the offering.

Key Decisions for Investors

• Investors should anticipate near-term downward pressure on TRVI's stock price due to the dilutive impact of the offering and the $5.75 issue price being significantly below recent trading levels.
• Consider the strategic importance of this capital raise, as the approximately $100 million in gross proceeds is vital for funding the clinical progression of Haduvio, which represents the primary potential value driver for Trevi Therapeutics.
• Closely monitor Haduvio's clinical trial results, future capital management, and the company's cash burn rate, as these factors will be critical determinants of long-term shareholder value.
• Re-evaluate positions based on individual risk tolerance, acknowledging that while the funding de-risks the immediate financial runway, clinical-stage biotechnology investments carry inherent development and regulatory approval risks, now compounded by shareholder dilution.